MOUNTAIN VIEW, Calif., March 19 VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Barclays Capital 2010 Global Healthcare Conference.
The VIVUS presentation will take place at the Loews Miami Beach Hotel in Miami, FL on Wednesday, March 24, 2010 at 3:15 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, QnexaŽ, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSEŽ (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT: VIVUS, Inc. Investor Relations: The Trout Group Timothy E. Morris Brian Korb Chief Financial Officer 646-378-2923 650-934-5200 Media Relations: Pure Communications, Inc. Dan Budwick 973-271-6085
SOURCE VIVUS, Inc.